Syndax Pharmaceuticals (NASDAQ:SNDX) Upgraded to “Hold” at Wall Street Zen

Wall Street Zen upgraded shares of Syndax Pharmaceuticals (NASDAQ:SNDX) from a sell rating to a hold rating in a research report report published on Saturday.

Several other research firms also recently weighed in on SNDX. BTIG Research reissued a “buy” rating and issued a $56.00 price target on shares of Syndax Pharmaceuticals in a research note on Tuesday, December 9th. Barclays boosted their target price on Syndax Pharmaceuticals from $22.00 to $35.00 and gave the company an “overweight” rating in a research note on Monday, November 24th. Weiss Ratings restated a “sell (d-)” rating on shares of Syndax Pharmaceuticals in a research report on Monday, December 29th. JPMorgan Chase & Co. decreased their price target on Syndax Pharmaceuticals from $40.00 to $33.00 and set an “overweight” rating on the stock in a research note on Wednesday, November 12th. Finally, UBS Group increased their price objective on Syndax Pharmaceuticals from $35.00 to $38.00 and gave the company a “buy” rating in a research note on Tuesday, November 4th. One analyst has rated the stock with a Strong Buy rating, nine have issued a Buy rating, one has given a Hold rating and one has given a Sell rating to the stock. According to data from MarketBeat, the stock has an average rating of “Moderate Buy” and a consensus target price of $37.20.

Syndax Pharmaceuticals Price Performance

Shares of NASDAQ:SNDX opened at $21.01 on Friday. The company’s fifty day moving average price is $20.67 and its 200-day moving average price is $17.02. The company has a debt-to-equity ratio of 2.78, a current ratio of 4.64 and a quick ratio of 4.42. The firm has a market capitalization of $1.83 billion, a price-to-earnings ratio of -5.82 and a beta of 0.46. Syndax Pharmaceuticals has a one year low of $8.58 and a one year high of $22.73.

Insiders Place Their Bets

In other Syndax Pharmaceuticals news, CFO Keith A. Goldan sold 2,082 shares of Syndax Pharmaceuticals stock in a transaction that occurred on Friday, February 6th. The shares were sold at an average price of $20.62, for a total value of $42,930.84. Following the completion of the sale, the chief financial officer owned 143,839 shares of the company’s stock, valued at approximately $2,965,960.18. The trade was a 1.43% decrease in their position. The transaction was disclosed in a document filed with the SEC, which is accessible through this hyperlink. Also, CEO Michael A. Metzger sold 7,412 shares of the stock in a transaction dated Friday, February 6th. The shares were sold at an average price of $20.62, for a total value of $152,835.44. Following the completion of the transaction, the chief executive officer directly owned 508,849 shares in the company, valued at approximately $10,492,466.38. This represents a 1.44% decrease in their position. Additional details regarding this sale are available in the official SEC disclosure. 4.10% of the stock is currently owned by insiders.

Institutional Investors Weigh In On Syndax Pharmaceuticals

A number of institutional investors and hedge funds have recently added to or reduced their stakes in SNDX. PSP Research LLC purchased a new position in Syndax Pharmaceuticals in the 4th quarter worth approximately $519,000. Profund Advisors LLC lifted its stake in Syndax Pharmaceuticals by 94.8% in the fourth quarter. Profund Advisors LLC now owns 60,038 shares of the company’s stock worth $1,261,000 after purchasing an additional 29,221 shares during the last quarter. ProShare Advisors LLC boosted its position in shares of Syndax Pharmaceuticals by 9.9% during the fourth quarter. ProShare Advisors LLC now owns 19,388 shares of the company’s stock valued at $407,000 after buying an additional 1,749 shares during the period. HighTower Advisors LLC grew its stake in shares of Syndax Pharmaceuticals by 8.7% during the fourth quarter. HighTower Advisors LLC now owns 18,940 shares of the company’s stock valued at $398,000 after buying an additional 1,517 shares during the last quarter. Finally, DNB Asset Management AS increased its stake in Syndax Pharmaceuticals by 27.8% in the 4th quarter. DNB Asset Management AS now owns 29,760 shares of the company’s stock worth $625,000 after buying an additional 6,466 shares during the period.

Syndax Pharmaceuticals Company Profile

Syndax Pharmaceuticals is a clinical-stage biopharmaceutical company dedicated to developing novel therapies for the treatment of cancer. Headquartered in Waltham, Massachusetts, the company focuses on small-molecule inhibitors that target key epigenetic and protein interaction pathways. Syndax’s research platform aims to enhance the effectiveness of existing therapies and address high unmet medical needs in oncology.

The company’s lead investigational candidate, entinostat, is a selective class I histone deacetylase (HDAC) inhibitor being evaluated for multiple solid tumor and hematologic indications.